Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.005
Neutral
RSI(14)
45.047
Neutral
STOCH(KDJ)(9,3,3)
32.694
Buy
ATR(14)
0.091
High Vlolatility
CCI(14)
-77.235
Neutral
Williams %R
62.056
Sell
TRIX(12,20)
-0.471
Sell
StochRSI(14)
100.000
Buy
AIM ImmunoTech Inc
AIM1.155USD
-0.055-4.55%
Market hours （ET）Quotes delayed by 15 min
3.20MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of AIM ImmunoTech Inc
Currency: USD Updated: 2026-02-02Key Insights
AIM ImmunoTech Inc's fundamentals are relatively stable, and its growth potential is significant.Its valuation is considered fairly valued, ranking 140 out of 393 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 21.98.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
AIM ImmunoTech Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
AIM ImmunoTech Inc Highlights
StrengthsRisks
AIM ImmunoTech Inc. is an immuno-pharma company. The Company is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) and highly selective TLR3 agonist immuno-modulator, which is being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe chronic fatigue syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 20.57% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 170.00K.
Overvalued
The company’s latest PE is -0.07, at a high 3-year percentile range.
Held by The Vanguard
Star Investor The Vanguard holds 17.52K shares of this stock.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
21.978
Target Price
+1811.13%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-02-02The current financial score of AIM ImmunoTech Inc is 5.79, ranking 325 out of 393 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 26.00K, representing a year-over-year decrease of 25.71%, while its net profit experienced a year-over-year decrease of 11.24%.
Score
Financials
5.24
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
8.22
Operational Efficiency
2.83
Growth Potential
5.59
Shareholder Returns
7.07
AIM ImmunoTech Inc's Company Valuation
Currency: USD Updated: 2026-02-02The current valuation score of AIM ImmunoTech Inc is 8.92, ranking 6 out of 393 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.07, which is -23.09% below the recent high of -0.05 and -61008.97% above the recent low of -41.55.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 140/393
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-02-02The current earnings forecast score of AIM ImmunoTech Inc is 8.00, ranking 164 out of 393 in the Biotechnology & Medical Research industry. The average price target is 22.00, with a high of 22.00 and a low of 22.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
21.978
Target Price
+1811.13%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
542
Total
6
Median
6
Average
Company name
Ratings
Analysts
AIM ImmunoTech Inc
AIM
1
CRISPR Therapeutics AG
CRSP
29
IQVIA Holdings Inc
IQV
26
argenx SE
ARGX
26
Beigene Ltd
ONC
24
Intellia Therapeutics Inc
NTLA
24
1
2
3
...
109
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-02-02The current price momentum score of AIM ImmunoTech Inc is 6.61, ranking 214 out of 393 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 1.37 and the support level at 1.07, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
1.188
Sell
MA10
1.196
Sell
MA20
1.248
Sell
MA50
1.326
Sell
MA100
1.843
Sell
MA200
3.205
Sell
Institutional Confidence
Currency: USD Updated: 2026-02-02Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
DRW Securities, LLC
Equels (Thomas K)
Kellner (Theodore D)
Sabby Management, LLC
Deutsch (Todd A)
Geode Capital Management, L.L.C.
Mitchell (William M)
Rodino (Peter W III)
Appelrouth (Stewart L.)
1
2
Risk Assessment
Currency: USD Updated: 2026-02-02The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of AIM ImmunoTech Inc is 2.01, ranking 261 out of 393 in the Biotechnology & Medical Research industry. The company's beta value is 1.26. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.
Score
Beta vs S&P 500 index
--
VaR
--
240-Day Maximum Drawdown
--
240-Day Volatility
--
Return
Best Daily Return
60 days
--
120 days
--
5 years
--
Worst Daily Return
60 days
--
120 days
--
5 years
--
Sharpe Ratio
60 days
--
120 days
--
5 years
--
Risk Assessment
Maximum Drawdown
240 days
--
3 years
--
5 years
--
Return-to-Drawdown Ratio
240 days
--
3 years
--
5 years
--
Skewness
240 days
--
3 years
--
5 years
--
Volatility
Realised Volatility
240 days
--
5 years
--
Standardised True Range
240 days
--
5 years
--
Downside Risk-Adjusted Return
120 days
--
240 days
--
Maximum Daily Upside Volatility
60 days
--
Maximum Daily Downside Volatility
60 days
--
Liquidity
Average Turnover Rate
60 days
--
120 days
--
5 years
--
Turnover Deviation
20 days
--
60 days
--
120 days
--
Peer Comparison
Biotechnology & Medical Research
AIM ImmunoTech Inc
AIM
6.21 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.62 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.55 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.51 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Viridian Therapeutics Inc
VRDN
8.42 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.39 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
